Popular drugs for diabetes and weight loss could have an unexpected side effect. Glucagon-like peptide 1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked ...
For patients, a new diagnosis of diabetes can be overwhelming. It means not only managing blood sugar but also preventing serious future health complications such as diabetic retinal disease, a ...
November is Diabetes-related Eye Disease Awareness Month, and early detection and treatment of diabetes are key to reduce the risk for significant vision loss and blindness, according to Prevent ...
Type 2 diabetes is among the top causes of vision loss and blindness across the world. According to studies, visual impairment due to diabetic retinopathy has increased significantly in the last 20 ...
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and fenofibrates are associated with a reduced risk for diabetic macular edema (DME) in patients with type 2 diabetes, while calcium channel ...
Headlines warning about “Ozempic blindness” may be frightening to the millions of people taking a GLP-1 drug to treat Type 2 diabetes or for weight loss. It's not an official diagnosis, but an ...
Share on Pinterest New research links GLP-1 medications such as semaglutide and tirzepatide to a doubled risk of potentially blinding eye diseases. Javier Zayas Photography/Getty Images The most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback